跳至主要内容
临床试验/IRCT20190628044046N1
IRCT20190628044046N1招募中3 期

Determining the Preventive Effect of Carvedilol on Reducing Transtosomab Cardiac Complications in Patients With Early Stages of HER2-Breast Cancer

Tehran University of Medical Sciences0 个研究点目标入组 60 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
招募中
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
no limit 至 no limit(—)
性别
All

入选标准

  • Patients who have recently been diagnosed with breast cancer (HER2-overexpressing) (stage I to IIIA) and are candidates for adjuvant treatment with trastuzumab.
  • The ability to have an informed consent.

排除标准

  • Left Ventricular Ejection Fraction (LVEF) baseline less than 50%, history of heart failure.
  • Contraindication of treatment with or receiving drugs for beta blocker(BB).
  • cardiomyopathy or valvular heart disease, myocardial infarction, uncontrolled blood pressure.
  • history of radiotherapy or chest chemotherapy to the chest.
  • filtration Glomerular volume 30 mL / min / 1.73 m2, which is calculated using the Modification of Diet in Renal Disease (MDRD)method.

研究者

相似试验